Related Experiment Videos
Role of platelets in progressive glomerular diseases
Insights
Platelets contribute to glomerulonephritis by releasing substances that damage glomeruli. While platelet inhibitors show promise, clinical results are inconclusive, necessitating further research into targeted therapies for progressive renal disease.
Area of Science:
- Nephrology
- Hematology
- Immunology
Background:
- Platelets are increasingly implicated in glomerulonephritis pathogenesis.
- Intraglomerular platelets and their products are found in various nephritis biopsies.
- Shortened platelet survival is observed in patients with glomerular diseases.
Purpose of the Study:
- To review the role of platelets in glomerulonephritis.
- To discuss platelet-derived mediators and their impact on glomerular injury and disease progression.
- To evaluate the efficacy of anti-platelet therapies in progressive renal disease.
Main Methods:
- Review of existing literature on platelet involvement in experimental and human glomerulonephritis.
- Analysis of platelet-derived factors such as platelet-activating factor, platelet factor 4, beta-thromboglobulin, platelet-derived growth factor (PDGF), and transforming growth factor beta (TGF-β).
- Examination of clinical study results for anti-platelet agents in progressive renal disease.
Main Results:
- Platelets release vasoactive, chemotactic, and mitogenic substances that amplify glomerular injury.
- Platelet products alter glomerular permeability and enhance immune-mediated injury.
- PDGF and TGF-β mediate disease progression, with inhibitors showing efficacy in experimental models.
Conclusions:
- Platelets play a significant role in glomerulonephritis through complex mechanisms.
- Current anti-platelet therapies have controversial clinical efficacy.
- Targeted inhibitors for platelet products are crucial for future therapeutic strategies.
Abstract:
There is increasing evidence that platelets are involved in the pathogenesis of glomerulonephritis. Intraglomerular platelets or their degradation products are observed in biopsies from patients with lupus nephritis, mesangioproliferative, membranous or IgA nephropathy. Moreover shortened platelet survival in patients with various glomerular diseases has also been described. In models of experimental glomerulonephritis, platelets may participate in glomerular injury, together with other mediators, by complex mechanisms. As extensively documented, platelets release within the glomerulus vasoactive, chemotactic and mitogenic substance that interact with a number of soluble mediators generated by renal resident or inflammatory cells and contribute to amplify glomerular injury. Thus platelet-activating factor and other platelet secretory products, polycationic macromolecules, platelet factor 4 and beta-thromboglobulin, alter glomerular permeability to proteins and enhance immune-mediated glomerular injury. Platelet-derived factors, like platelet-derived growth factor (PDGF) and transforming growth factor beta (TGF beta) mediate renal disease progression in experimental and human glomerulonephritis via their chemotactic activity for infiltrating leucocytes and their effect of promoting extracellular matrix synthesis by resident renal cells. In these settings increased renal expression of PDGF and TGF beta has correlated with clinical features. Specific PDGF and TGF beta inhibitors ameliorated experimental glomerular disease. A wide variety of therapies to inhibit platelet function have been employed over the years, however the results of clinical studies are controversial and do not allow conclusions to be drawn about the efficacy of anti-platelet agents in progressive renal disease. Identification of specific platelet inhibitors or interventions specific for platelet secretory products and their target cells will be crucial for understanding the exact role of platelets and their products in glomerular disease.